Article
Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
15 Feb 2019
Abstract excerpt
Immunotherapy with chimeric antigen receptor (CAR) T cells offers a promising method to improve cure rates and decrease morbidities for patients with cancer. In this regard, CD19-specific CAR T cell therapies have achieved dramatic objective responses for a high percent of patients with CD19-positive leukemia or lymphoma. Most patients with solid tumors however, have experienced transient or no benefit from CAR T...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
